The partnership with Formation Bio and OpenAI positions Sanofi at the forefront of AI integration in biopharma. By leveraging proprietary data to develop AI models, Sanofi aims to enhance its drug development process and improve patient access to new medicines. This strategic move is likely to positively impact Sanofi's stock in the short term as it demonstrates innovation and forward-thinking in the industry.